CG Oncology, Inc. Common stock

CGONNASDAQ • USD
ThemeHealthcare - Oncology›Immunotherapy & Immuno-Oncology
74.85 USD
↗ 2.43 (3.36%)AT CLOSE (11:59 AM EDT)
74.80
↘ 0.05 (0.07%)
POST MARKET (AS OF 07:46 PM EDT)
Post Market
AS OF 07:46 PM EDT
74.80
↘ 0.05 (0.07%)
🔴Market: CLOSED

CGON is currently priced at $74.73. There is a divergence between signals — technical indicators rate "Strong Buy" but underlying fundamentals lean "Sell". This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 2/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. On the valuation front, CGON trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.

Technical & fundamental data as of Aug 6, 2026.

Open?$71.85
High?$76.50
Low?$71.85
Prev. Close?$72.42
Volume?936.1K
Avg. Volume?1.1M
VWAP?$74.94
Rel. Volume?0.84x
Bid / Ask
Bid?$63.45 × 100
Ask?$85.12 × 100
Spread?$21.67
Midpoint?$74.29
Valuation & Ratios
Market Cap?6.4B
Shares Out?88.2M
Float?55.6M
Float %?68.9%
P/E Ratio?N/A
P/B Ratio?5.85
EPS?-$2.12
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Themes
Healthcare - Oncology›Immunotherapy & Immuno-OncologyBiotech - Drug Development›Clinical-Stage Platforms
Employees
142
Market Cap
6.4B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.cgoncology.com
Listed
2024-01-25
Address
3000 PEGASUS PARK DRIVE
DALLAS, TX 75247
Phone: (949) 409-3700
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
12
Z-Score?
100
Momentum?
18
Short Sent.?
19
Piotroski F-Score?2/9Weak
Altman Z-Score?88.11Safe
Confidence?55%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?21.77%Squeeze Risk
Short Interest?12.1M
Days to Cover?12.2
Free Float55.6M
Avg Daily Volume989.4K
Settlement Date2026-07-15
Financial Health
Current Ratio?31.30Strong
Quick Ratio?31.25Strong
Cash Ratio?0.96Adequate
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
58/100
P/E?
N/A▾
P/B?
Peers
100
S&P
32
5.85FAIR▾
P/S?
Peers
100
S&P
3
1,259.64HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-29.9CHEAP▾
EV/Sales?
Peers
100
S&P
3
1,253.58HIGH▾
Returns & Efficiency
ROE?
S&P
8
-17.1%WEAK▾
ROA?
S&P
3
-16.5%WEAK▾
Cash Flow & Enterprise
FCF?$-160434000
Enterprise Value?$6.4B
Fundamentals ratios updated end of day
MarketsMoversWatchlist